Childhood Anti-NMDA Receptor Encephalitis

Area of Science:

• Pediatric Neurology
• Immunology
• Neuroscience

Background:

• Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune disorder affecting the central nervous system.
• It is a significant cause of treatable encephalitis, particularly in children and young adults.

Purpose of the Study:

• To investigate the clinical characteristics and treatment outcomes of pediatric patients diagnosed with anti-NMDAR encephalitis.
• To highlight the importance of early diagnosis and aggressive immunotherapy for improved patient prognosis.

Main Methods:

• A retrospective case series involving children under 12 years old diagnosed with anti-NMDAR encephalitis.
• Data collected from May 2013 to June 2015 at a tertiary care institute.

Main Results:

• Six out of twenty suspected pediatric cases tested positive for anti-NMDAR antibodies.
• Presenting symptoms included behavioral changes, psychosis, seizures, and dyskinesia; all patients exhibited irritability, insomnia, and mutism.
• First-line immunotherapy (IV methylprednisolone, IVIg) was ineffective in most cases, necessitating second-line treatments like rituximab and cyclophosphamide.

Conclusions:

• Anti-NMDAR encephalitis is a rare but treatable neurological condition in children.
• Prompt recognition and distinct treatment strategies, differing from viral encephalitis, are essential.
• Aggressive immunotherapy, often requiring second-line agents, is critical for achieving favorable outcomes.